CMTM6 and breast carcinoma: A previous study found that the dual knockdown of CMTM6 and CMTM7 observably downregulated the expression of PD-L1 in the breast cancer cell line MCF-7Mes (Xiao et al., 2021), indicating the potential role of CMTM7 in reflecting the anti-tumor activity of BRCA.